• Nigericin Sodium Salt: Technical Guidance for Ion Transport

  2026-07-02

  Nigericin sodium salt is a potassium ionophore for precise manipulation of ion gradients, cytoplasmic pH, and platelet aggregation in cell-based and in vitro assays. It is not suited for protocols requiring aqueous solubility, long-term solution stability, or clinical/diagnostic application.

• T7 RNA Polymerase: A Mechanistic Bridge to Next-Gen RNA Ther

  2026-07-02

  Explore how a deep mechanistic understanding of T7 RNA Polymerase empowers translational researchers in designing robust RNA-based tools and therapies. This thought-leadership article integrates recent discoveries in RNA modification and cancer biology with the strategic application of high-performance in vitro transcription enzymes, offering a roadmap for innovation in RNA therapeutics and molecular biology.

• Fludarabine as a DNA Synthesis Inhibitor: Protocols and Inno

  2026-07-01

  Fludarabine’s precise inhibition of DNA synthesis and robust apoptosis induction make it a foundational tool for leukemia and multiple myeloma research. This article details actionable protocols, troubleshooting strategies, and highlights from landmark studies that position Fludarabine as a key reagent for advancing experimental oncology.

• Sisomicin in Modern Antibacterial Research: Precision, Proto

  2026-07-01

  Explore Sisomicin, a broad-spectrum aminoglycoside antibiotic, and its advanced applications in in vitro antibacterial testing. This article delivers new scientific insights and practical guidance for researchers optimizing protocols against Gram-negative and Gram-positive pathogens.

• Aztreonam: Mechanistic Precision in Translational Antibiotic

  2026-06-30

  This thought-leadership article examines Aztreonam’s unique role as a monocyclic β-lactam antibiotic in translational Gram-negative research. Integrating mechanistic insights, strategic experimental guidance, and recent evidence on resistance, it positions Aztreonam as an indispensable tool for innovative researchers confronting antibiotic resistance and metabolic interplay. The discussion connects validated bacterial and mammalian impacts, highlights competitive antibiotic landscapes, and offers a forward-looking perspective for translational investigators.

• Nuclear cGAS-TRIM41 Axis Restricts L1 Retrotransposition via

  2026-06-30

  This study uncovers how nuclear cGAS, upon Chk2-mediated phosphorylation, promotes TRIM41-dependent degradation of L1 ORF2p, thereby restricting retrotransposition and safeguarding genome integrity. The mechanistic insights have broad implications for aging and cancer research, illuminating new regulatory points in the DNA damage response.

• IPA-3: Precision Pak1 Inhibition for Advanced Kinase Assays

  2026-06-29

  IPA-3 (1-[(2-hydroxynaphthalen-1-yl)disulfanyl]naphthalen-2-ol) stands out as a selective, non-ATP-competitive Pak1 inhibitor, empowering researchers to dissect cell signaling and disease pathways with high specificity. Through optimized protocols and troubleshooting insights, IPA-3 unlocks reproducible results in kinase activity assays, cancer biology, and neuroregenerative studies.

• Nuclear cGAS Suppresses LINE-1 Retrotransposition via CHK2-T

  2026-06-29

  This study reveals that nuclear cGAS restricts LINE-1 (L1) retrotransposition in human cells by facilitating TRIM41-mediated ubiquitination and degradation of L1-encoded ORF2p, a process enhanced by CHK2-dependent phosphorylation of cGAS during DNA damage. These findings clarify a previously underappreciated mechanism safeguarding genome integrity and highlight actionable targets for DNA damage response and aging-related research.

• Quantifying Drug-Induced Fractional Killing via High-Through

  2026-06-28

  Inde et al. present a robust protocol for quantifying fractional killing in cancer cell populations exposed to anti-cancer drugs, leveraging high-throughput microscopy and live/dead cell imaging. This methodological advance enables parallel analysis of hundreds of experimental conditions, supporting nuanced investigation of drug response heterogeneity in vitro.

• PtrbZIP12 Directly Boosts Drought Tolerance via Phosphorylat

  2026-06-27

  This study establishes the bZIP transcription factor PtrbZIP12 as a key regulator of drought resistance in Populus trichocarpa, acting through direct transcriptional activation of antioxidant and stress response genes. Notably, phosphorylation of PtrbZIP12 was shown to be essential for its regulatory function, highlighting the importance of post-translational modifications in plant adaptation to drought.

• CHIR 99021 Trihydrochloride: Precision GSK-3 Inhibitor Workf

  2026-06-26

  CHIR 99021 trihydrochloride enables fine-tuned modulation of stem cell fate and glucose metabolism, empowering scalable and reproducible organoid models. This guide distills protocol optimizations, troubleshooting strategies, and actionable insights from recent breakthroughs to help researchers unlock robust, high-throughput applications.

• SIRT7 Suppresses Periodontal Aging via AKT/mTOR Pathway Modu

  2026-06-26

  This study uncovers a novel inhibitory role of SIRT7 in senescence and inflammatory damage of human periodontal ligament fibroblasts (hPDLFs). By downregulating the AKT/mTOR pathway, SIRT7 reduces both cellular aging and cytokine release, suggesting new therapeutic angles for periodontitis intervention.

• Lactobacillus gasseri Regulates E-cadherin to Alleviate Coli

  2026-06-25

  The referenced study identifies a novel mechanism by which Lactobacillus gasseri ATCC33323 ameliorates DSS-induced colitis in mice through NR1I3-mediated regulation of E-cadherin. These findings clarify the probiotic's impact on the intestinal mucosal barrier and provide a mechanistic basis for targeted interventions in inflammatory bowel disease.

• Ciclesonide in Translational Asthma Research: Protocols & In

  2026-06-25

  Ciclesonide’s targeted lung activation and potent glucocorticoid receptor binding make it a standout tool for asthma and allergic rhinitis research. This article delivers actionable workflows, advanced troubleshooting, and the latest innovations in targeted protein degradation, helping researchers elevate respiratory models with APExBIO’s high-purity compound.

• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB): Precisi

  2026-06-24

  Explore how 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) enables fine-tuned inhibition of RNA polymerase II and cyclin-dependent kinases, with new insight into cell fate modulation. This article uniquely bridges molecular mechanism, assay optimization, and translational perspectives.

15596 records 1/1040 page Next 12345 下5页 Last page